Production of recombinant immunotherapeutics for anticancer treatment

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Bioengineered

• Publication date

  2013-04-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/bioe.24666PMID 23644447PMCID PMC3813530
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted therapy for metastatic colorectal cancer: role of aflibercept.

  2013cited by this paper
• Production of bispecific antibodies: diabodies and tandem scFv.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Therapeutic cancer vaccines: current status and moving forward.

  2012cited by this paper
• A preclinical and clinical review of aflibercept for the management of cancer.

  2012cited by this paper
• Cancer immunotherapy

  2012cited by this paper
• Genetically engineered fusion proteins for treatment of cancer.

  2012cited by this paper
• Monoclonal antibodies in cancer therapy.

  2012cited by this paper
• Therapeutic application of monoclonal antibodies in cancer: advances and challenges.

  2012cited by this paper
• Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma

  2012cited by this paper
• Pharmacology and therapeutic potential of interferons.

  2012cited by this paper
• Treating Cancer with Vaccine

  2012influential reference
• Therapeutic targets and recent advances in protein immunotoxins.

  2012cited by this paper
• The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

  2012cited by this paper
• Cancer vaccines

  2011cited by this paper
• Cancer immunotherapy.

  2011cited by this paper
• Recent Developments in Cancer Vaccines

  2011cited by this paper
• Multifunctional vaccines in cancer: the ‘triad’ approach

  2011cited by this paper
• Therapeutic potential of anticancer immunotoxins.

  2011cited by this paper
• Improvement of different vaccine delivery systems for cancer therapy

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• New approaches to treat cancer - what they can and cannot do.

  2011cited by this paper
• Antibodies in oncology.

  2011cited by this paper
• Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond

  2011cited by this paper
• Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

  2011cited by this paper
• Recombinant antibodies: Engineering and production in yeast and bacterial hosts

  2011cited by this paper
• Engineering of Therapeutic Proteins Production in Escherichia coli

  2011cited by this paper
• Production of antibodies in plants: status after twenty years.

  2010cited by this paper
• Development trends for human monoclonal antibody therapeutics

  2010cited by this paper
• Therapeutic antibodies for autoimmunity and inflammation

  2010cited by this paper
• Cancer Vaccines: A Promising Role in Cancer Therapy

  2010cited by this paper
• Vaccines and Immunotherapeutics for the Treatment of Malignant Disease

  2010cited by this paper
• Prophylaxis of Cervical Cancer and Related Cervical Disease: A Review of the Cost-Effectiveness of Vaccination Against Oncogenic HPV Types

  2010cited by this paper
• Strategies for Cancer Vaccine Development

  2010cited by this paper
• Bacteria in cancer therapy: a novel experimental strategy

  2010cited by this paper
• Monoclonal antibodies: versatile platforms for cancer immunotherapy

  2010cited by this paper
• Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

  2010cited by this paper
• The safety and side effects of monoclonal antibodies

  2010cited by this paper
• Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

  2010cited by this paper
• Different spectra of therapeutic vaccine development against HPV infections

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Monoclonal antibody therapy

  2009cited by this paper
• HPV & HPV vaccination: issues in developing countries.

  2009cited by this paper
• Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?

  2008cited by this paper
• Engineering therapeutic monoclonal antibodies

  2008cited by this paper
• Monoclonal antibodies in cancer therapy: 25 years of progress.

  2008cited by this paper
• FDA drug approval summary: panitumumab (Vectibix).

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Cancer vaccines: preclinical studies and novel strategies.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Cancer vaccines

  2005cited by this paper
• Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Monoclonal antibodies in cancer therapy

  2004cited by this paper
• Rituximab (Rituxan®/MabThera®): the first decade (1993–2003)

  2003cited by this paper
• Vaccines and Immunostimulants

  2003cited by this paper
• History of antibody therapy for non-Hodgkin's lymphoma.

  2003cited by this paper
• Domain antibodies: proteins for therapy.

  2003cited by this paper
• Clinical Experience with Trastuzumab (Herceptin)

  2003cited by this paper
• Designing immunotoxins for cancer therapy

  2002cited by this paper
• The ErbB receptor family: a therapeutic target for cancer.

  2002cited by this paper
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Vaccines, coming of age after 200 years.

  2000cited by this paper
• Vaccines, Coming of Age after 200 Years

  1999cited by this paper
• Immunotoxins for targeted cancer therapy.

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998cited by this paper
• [TUMOR IMMUNOLOGY].

  1963cited by this paper

• Recombinant L-asparaginase from Stenotrophomonas maltophilia: a promising low-immunogenic anticancer agent

  2025cites this paper
• Recent Findings on Therapeutic Cancer Vaccines: An Updated Review

  2024cites this paper
• Uveitis Following Intravitreal Injections of Faricimab: A Case Report

  2023cites this paper
• Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents.

  2022cites this paper
• The role of Tripartite motif containing 59 (TRIM59) in the proliferation and prognosis of intrahepatic cholangiocarcinoma.

  2022cites this paper
• Salivary potassium measured by genetically encoded potassium ion indicators as a surrogate for plasma potassium levels in hemodialysis patients - a proof-of-concept study.

  2022cites this paper
• Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review

  2021cites this paper
• Cancer Immunotherapy

  2021cites this paper
• Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs

  2021cites this paper
• Antimicrobial activities and mechanism of action of Cymbopogon khasianus (Munro ex Hackel) Bor essential oil

  2020cites this paper
• Apoptin as a Tumor-Specific Therapeutic Agent: Current Perspective on Mechanism of Action and Delivery Systems

  2020cites this paper
• Comparative analytical profiling of bevacizumab biosimilars marketed in India: a national control laboratory study

  2020cites this paper
• Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing

  2019cites this paper
• Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity

  2018cites this paper
• Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

  2017cites this paper
• CAR-modified T-cell therapy for cancer: an updated review

  2016cites this paper
• Bioengineered non-coding RNA agent (BERA) in action

  2016cites this paper
• Immune-O-Toxins as the magic bullet for therapeutic purposes

  2015cites this paper
• Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.

  2014cites this paper
• Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.

  2013cites this paper
• A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

  2013cites this paper